# Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss

> **NCT00471510** · PHASE2 · UNKNOWN · sponsor: **Neosil, Inc.** · enrollment: 140 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** tetrapeptide aldehyde proteasome inhibitor (NEOSH101)

## Key facts

- **NCT ID:** NCT00471510
- **Lead sponsor:** Neosil, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-05
- **Primary completion:** 2008-02
- **Final completion:** —
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2008-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471510, "Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00471510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*